Related Experiment Video
Updated: May 3, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Cardiac sarcoidosis: the Christchurch experience
P Adamson1, I Melton, J O'Donnell
1Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand.
Insights
Cardiac sarcoidosis diagnosis and treatment were reviewed in 18 patients. Cardiac magnetic resonance imaging (CMR) showed high sensitivity, while biomarkers were often normal. Most patients received immunosuppression and cardiac devices, with lower-than-expected long-term mortality.
Area of Science:
- Cardiology
- Immunology
- Internal Medicine
Background:
- Cardiac sarcoidosis is a rare but serious condition affecting the heart.
- Early diagnosis and treatment are crucial for improving patient outcomes.
Purpose of the Study:
- To provide an overview of the diagnosis, treatment, and outcomes of cardiac sarcoidosis patients.
- To evaluate the utility of cardiac magnetic resonance imaging (CMR) and biomarkers in diagnosing cardiac sarcoidosis.
- To assess the effectiveness of current treatment strategies, including immunosuppression and cardiac device implantation.
Main Methods:
- Retrospective review of 18 patients diagnosed with cardiac sarcoidosis between 2005 and 2012.
- Analysis of diagnostic tools including cardiac magnetic resonance imaging (CMR), angiotensin-converting enzyme (ACE) levels, cardiac troponin (cTn), and endomyocardial biopsies.
- Review of treatment modalities such as immunosuppressive therapy and cardiac device implantation (pacemakers, defibrillators).
Main Results:
- Cardiac magnetic resonance imaging (CMR) demonstrated high diagnostic sensitivity, with all 12 patients scanned showing abnormalities.
- Biomarkers like angiotensin-converting enzyme (ACE) and cardiac troponin (cTn) were frequently within normal limits.
- The primary presentations were high-grade atrioventricular conduction block and congestive heart failure (6 patients each), followed by ventricular tachycardia and atrial fibrillation.
- Most patients (16/18) received immunosuppressive therapy, and 12 patients had cardiac devices implanted.
- During a median follow-up of 4.8 years, only two patients died.
Conclusions:
- Cardiac magnetic resonance imaging (CMR) is a highly sensitive tool for diagnosing cardiac sarcoidosis.
- Biomarkers (ACE, cTn) have limited diagnostic value in this patient cohort.
- Cardiac sarcoidosis frequently leads to significant arrhythmias or heart failure.
- Treatment with immunosuppression and cardiac devices is effective, and long-term mortality appears lower than previously reported.
Background And Aims:
To present an overview of the diagnosis, treatment and outcomes of patients with cardiac sarcoidosis managed in Christchurch Hospital, New Zealand.
Methods:
A retrospective review of patients with cardiac sarcoidosis at Christchurch Hospital from January 2005 to December 2012.
Results:
Eighteen patients were identified with cardiac sarcoidosis. All the 12 patients that underwent cardiac magnetic resonance imaging (CMR) had abnormal scans. Angiotensin-converting enzyme (ACE) levels were elevated in 4 of 16 patients and troponin (cTn) was elevated in 5 of 15 patients. Endomyocardial biopsies were diagnostic in two of six patients. The principal causes for presentation related to symptomatic high-grade atrioventricular conduction block and congestive heart failure with six patients in each of these groups. In addition, three patients presented with ventricular tachycardia and the remaining three patients presented with atrial fibrillation, recurrent presyncope without proven heart block and an asymptomatic persistent elevation of cardiac troponin. Seven patients had pre-existing, extra-cardiac sarcoidosis and a concomitant diagnosis was made in a further eight cases. Three patients had isolated cardiac involvement at presentation. Sixteen patients received immunosuppressive therapy. Twelve patients had cardiac devices implanted; five pacemakers, five defibrillators and two resynchronising pacemaker defibrillators. During follow up for 0.1-30.8 years, median 4.8 years, two patients died.
Conclusions:
In our patients CMR demonstrated high diagnostic sensitivity, while biomarkers (ACE and cTn) were frequently within the normal reference range. Cardiac sarcoidodis caused major arrhythmias or heart failure in the majority of patients. Most patients were treated with immunosuppression and cardiac device therapy. Long-term mortality was lower than previously reported.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis II: Clinical Features and Diagnostic Tests
Pericarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
